TY - JOUR
T1 - Treatment Outcomes in the Tube Versus Trabeculectomy Study After One Year of Follow-up
AU - Primary Tube Versus Trabeculectomy Study Group
AU - Gedde, Steven
AU - Anderson, Douglas
AU - Budenz, Donald
AU - Del Calvo, Madeline
AU - Fantes, Francisco
AU - Greenfield, David
AU - Hodapp, Elizabeth
AU - Lee, Richard
AU - Marcellino, Alexia
AU - Palmberg, Paul
AU - Parrish, Richard
AU - Herndon, Leon
AU - Challa, Pratap
AU - Santiago-Turla, Cecile
AU - WuDunn, Darrell
AU - Emerick, Geoffrey
AU - Heuer, Dale
AU - Kent, Alexander
AU - Bradham, Carol
AU - Langdale, Lisa
AU - Barton, Keith
AU - Amalfitano, Francesca
AU - Rai, Poornima
AU - Sidoti, Paul
AU - Gedal, Amy
AU - Luayon, James
AU - Ovase, Roma
AU - Tai, Katy
AU - Nguyen, Quang
AU - Miller, Neva
AU - Shields, Steven
AU - Anderson, Kevin
AU - Moya, Frank
AU - Brandt, James
AU - Lim, Michele
AU - Sponzo, Marilyn
AU - Sherwood, Mark
AU - Burke, Revonda
AU - Skuta, Gregory
AU - Jobson, Jason
AU - Ogilbee, Lisa
AU - Reynolds, Adam
AU - Varma, Rohit
AU - Francis, Brian
AU - Walonker, Frances
AU - Feldman, Robert
AU - Baker, Laura
AU - Bell, Nicholas
AU - Carranza, Jo Lene
AU - Espinoza, Athena
N1 - Funding Information:
This study was supported by research grants from Pfizer, Inc, New York, New York, Advanced Medical Optics, Irvine, California, the National Eye Institute (Grant No. EY014801), National Institutes of Health, Bethesda, Maryland, and Research to Prevent Blindness, Inc, New York, New York. The authors indicate financial conflict of interest (see complete list of investigators at AJO.com .). All the authors and list of investigators were involved in design and conduct of the study, involved in collection, management, analysis, and interpretation of the data and involved in preparation, review, or approval of the manuscript.
Funding Information:
Keith Barton, M.D.: Pfizer, honoraria. James Brandt, M.D.: Pfizer, consultant, speakers bureau, honoraria; Advanced Medical Optics, consultant. Donald Budenz, M.D., M.P.H.: Pfizer, honoraria, speakers bureau. Philip Chen, M.D.: Pfizer, honoraria. Geoffrey Emerick, M.D.: Pfizer, honoraria, speakers bureau. Francisco Fantes, M.D.: Pfizer, speakers bureau. Robert Feldman, M.D.: Pfizer, consultant, grant support, honoraria, speakers bureau. Brian Francis, M.D.: Pfizer, speakers bureau. Steven Gedde, M.D.: Pfizer, honoraria, speakers bureau; Advanced Medical Optics, honoraria. David Greenfield, M.D.: Pfizer, consultant, honoraria, speakers bureau. Leon Herndon, M.D.: Pfizer, honoraria, speakers bureau. Dale Heuer, M.D.: Pfizer, honoraria, speakers bureau. Paul Kaufman, M.D.: Pfizer, consultant, grant support, honoraria, speakers bureau, travel expenses; Advanced Medical Optics, consultant, grant support. Richard Lee, M.D., Ph.D.: Pfizer, speakers bureau. Frank Moya, M.D.: Pfizer, speakers bureau. Quang Nguyen, M.D.: Pfizer, consultant, honoraria, speakers bureau. Paul Palmberg, M.D., Ph.D.: Pfizer, consultant, speakers bureau, honoraria. Richard Parrish II, M.D.: Pfizer, consultant, honoraria. Bruce Prum, M.D.: Pfizer, grant support, speakers bureau. Adam Reynolds, M.D.: Pfizer, honoraria. Steven Shields, M.D.: Pfizer, consultant. Kuldev Singh, M.D., M.P.H.: Pfizer, consultant. Gregory Skuta, M.D.: Pfizer, consultant, honoraria, speakers bureau. George Spaeth, M.D.: Pfizer, grant support, honoraria. Rohit Varma, M.D., M.P.H.: Pfizer, consultant, grant support, honoraria, speakers bureau. Martha Wright, M.D.: Pfizer, speakers bureau. Darrell WuDunn, M.D., Ph.D.: Pfizer, honoraria, speakers bureau.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Purpose: To report one-year results of the Tube Versus Trabeculectomy (TVT) Study. Design: Multicenter randomized clinical trial. Methods: setting: 17 Clinical Centers. study population: Patients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) ≥18 mm Hg and ≤40 mm Hg on maximum tolerated medical therapy. interventions: 350 mm2 Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC). main outcome measures: IOP, visual acuity, and reoperation for glaucoma. Results: A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group. At one year, IOP (mean ± SD) was 12.4 ± 3.9 mm Hg in the tube group and 12.7 ± 5.8 mm Hg in the trabeculectomy group (P = .73). The number of glaucoma medications (mean ± SD) was 1.3 ± 1.3 in the tube group and 0.5 ± 0.9 in the trabeculectomy group (P < .001). The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017). Conclusions: Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study. Both surgical procedures produced similar IOP reduction at one year, but there was less need for supplemental medical therapy following trabeculectomy with MMC.
AB - Purpose: To report one-year results of the Tube Versus Trabeculectomy (TVT) Study. Design: Multicenter randomized clinical trial. Methods: setting: 17 Clinical Centers. study population: Patients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) ≥18 mm Hg and ≤40 mm Hg on maximum tolerated medical therapy. interventions: 350 mm2 Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC). main outcome measures: IOP, visual acuity, and reoperation for glaucoma. Results: A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group. At one year, IOP (mean ± SD) was 12.4 ± 3.9 mm Hg in the tube group and 12.7 ± 5.8 mm Hg in the trabeculectomy group (P = .73). The number of glaucoma medications (mean ± SD) was 1.3 ± 1.3 in the tube group and 0.5 ± 0.9 in the trabeculectomy group (P < .001). The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017). Conclusions: Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study. Both surgical procedures produced similar IOP reduction at one year, but there was less need for supplemental medical therapy following trabeculectomy with MMC.
UR - http://www.scopus.com/inward/record.url?scp=33845486717&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2006.07.020
DO - 10.1016/j.ajo.2006.07.020
M3 - Article
C2 - 17083910
AN - SCOPUS:33845486717
SN - 0002-9394
VL - 143
SP - 22.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 1
ER -